The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature

Clinical Rheumatology

Volumn 35, Issue 5, 2016, Pages 1383-1388

  Scrivo, Rossana ^a   Sauzullo, Ilaria ^b   Mengoni, Fabio ^b   Riccieri, Valeria ^a   Altieri, Alfonso Maria ^c   Cantoro, Laura ^d   Vullo, Vincenzo ^b   Mastroianni, Claudio Maria ^a,b   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Adalimumab; IGRA; QuantiFERON TB Gold In Tube; Rheumatoid arthritis; TNF antagonists; Tuberculosis

Indexed keywords

ADALIMUMAB; CIPROFLOXACIN; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; MESALAZINE; METHOTREXATE; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; ANTIRHEUMATIC AGENT; TUBERCULOSTATIC AGENT;

ADULT; BODY TEMPERATURE; CASE REPORT; CROHN DISEASE; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PERUVIAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPLICATION; TUBERCULOSIS;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; LATENT TUBERCULOSIS; TUBERCULOSIS;

EID: 84901565984     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2669-0     Document Type: Review

References (35)

1. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 48(8):2122–2127
2. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345(15):1098–1104
3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infection diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261–1265
4. Winthrop KL, Weinblatt ME, Daley CL (2012) You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you need. Ann Rheum Dis 71(11):1757–1760
5. Scrivo R, Sauzullo I, Mengoni F et al (2013) Mycobacterial interferon-γ release variations during long-term treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 40(2):157–165
6. Kim KH, Lee SW, Chung WT et al (2011) Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 31(4):271–278
7. Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H (2012) Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 14(3):R147
8. Garcovich S, Ruggeri A, D'Agostino M et al (2012) Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 26(12):1572–1576
9. Drago L, Nicola L, Signori V et al (2013) Dynamic QuantiFERON response in psoriasis patients taking long-term biologic therapy. Dermatol Ther (Heidelb) 3(1):73–81
10. Sauzullo I, Mengoni F, Marocco R et al (2013) IFN-γ release assay for tuberculosis in psoriasis patients treated with TNF antagonists: in vivo and in vitro analysis. Br J Dermatol 169(5):1133–1140
11. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Ann Rheum Dis 71(2):231–237
12. Xie X, Chen JW, Li F, Tian J, Gao JS, Zhang D (2011) A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy. Clin Exp Med 11(3):155–161
13. Klein M, Jarošová K, Forejtová Š et al (2013) Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clin Exp Rheumatol 31(1):111–117
14. Pai M, O’Brien R (2007) Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 4(6):e208
15. Pai M, Dheda K, Cunningham J, Scano F, O’Brien R (2007) T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 7(6):428–438
16. Pai M, Joshi R, Dogra S et al (2009) T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 13(1):84–92
17. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A (2006) Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 174(7):831–839
18. Wilkinson KA, Kon OM, Newton SM et al (2006) Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 193(3):354–359
19. Goletti D, Parracino MP, Butera O et al (2007) Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 8:5
20. Higuchi K, Harada N, Mori T (2008) Interferon-γ responses after isoniazid chemotherapy for latent tuberculosis. Respirology 13(3):468–472
21. American Thoracic Society, Centers for Disease Control and Prevention (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161(4 Pt 2):S221–S247
22. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z (2003) Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 7(12 Suppl 3):384–390
23. LoBue PA, Moser KS (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168(4):443–447
24. Horsburgh CR Jr (2004) Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 350(20):2060–2067
25. Horsburgh CR Jr, Goldberg S, Bethel J, Tuberculosis Epidemiologic Studies Consortium et al (2010) Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 137(2):401–409
26. Iseman MD (2002) Tuberculosis therapy: past, present and future. Eur Respir J 36:S87–S94
27. Huebner RE, Schein MF, Bass JB Jr (1993) The tuberculin skin test. Clin Infect Dis 17(6):968–975
28. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64(9):1360–1361
29. Whitworth HS, Scott M, Connell DW, Dongés B, Lalvani A (2013) IGRAs—the gateway to T cell based TB diagnosis. Methods 61(1):52–62
30. Daley CL, Reves RR, Beard MA et al (2013) A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing. Infect Control Hosp Epidemiol 34(6):625–630
31. Barry CE 3rd, Boshoff HI, Dartois V et al (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845–855
32. Sester M, Sotgiu G, Lange C et al (2011) Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 37(1):100–111
33. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19:93–129
34. Rook GA (2007) Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 7(3):327–337
35. Dwivedi VP, Bhattacharya D, Chatterjee S et al (2012) Mycobacterium tuberculosis directs T helper 2 cell differentiation by inducing interleukin-1β production in dendritic cells. J Biol Chem 287(40):33656–33663